We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.
Evolving treatments for advanced gastric cancer: appraisal of the survival trend / Roberto, Michela; Romiti, Adriana; Onesti, CONCETTA ELISA; Zullo, Angelo; Falcone, Rosa; Marchetti, Paolo. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - STAMPA. - 16:(2016), pp. 717-729. [10.1080/14737140.2016.1184979]
Evolving treatments for advanced gastric cancer: appraisal of the survival trend
ROBERTO, MICHELA;ROMITI, ADRIANA;ONESTI, CONCETTA ELISA;FALCONE, ROSA;MARCHETTI, PAOLO
2016
Abstract
We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.